Outgrowth of minimal residual disease (MRD) in acute myeloid leukaemia (AML) is responsible for the occurrence of relapses. MRD can be quantified by immunophenotyping on a flow cytometer using the expression of leukaemia-associated phenotypes. MRD was monitored in follow-up samples taken from bone marrow (BM) of 72 patients after three different cycles of chemotherapy and from autologous peripheral blood stem cell (PBSC) products. The MRD% in BM after the first cycle (n ¼ 51), second cycle (n ¼ 52) and third cycle (n ¼ 30), as well as in PBSC products (n ¼ 39) strongly correlated with relapse-free survival. At a cutoff level of 1% after the first cycle and median cutoff levels of 0.14% after the second, 0.11% after the third cycle and 0.13% for PBSC products, the relative risk of relapse was a factor 6.1, 3.4, 7.2 and 5.7, respectively, higher for patients in the high MRD group. Also, absolute MRD cell number/ml was highly predictive of the clinical outcome. After the treatment has ended, an increase of MRD% predicted forthcoming relapses, with MRD assessment intervals of p3 months. In conclusion, MRD parameter assessment at different stages of disease is highly reliable in predicting survival and forthcoming relapses in AML.
Introduction
Minimal residual disease (MRD) cells, present in the bone marrow (BM) of patients with acute myeloid leukaemia (AML) after chemotherapy, are thought to be responsible for the emergence of a relapse. Monitoring of MRD cells by molecular biologic or immunophenotypic detection methods are thought to be of crucial value for defining individualized treatment of patients. Based on MRD frequencies patient-tailored postremission chemotherapy could be designed, which might reduce either the risk of relapse or, in case of withholding therapy to the patient, diminish morbidity and mortality. Also, when impending relapses can be predicted, these might be prevented by early therapeutic interventions. Furthermore, MRD frequency assessment can be used to quantify the leukaemia cell contamination of an autologous peripheral blood stem cell (PBSC) product in order to guide the decision of whether or not to purge, and in the latter case to establish the efficacy of leukaemia cell eradication.
Immunophenotypic detection of MRD by flow cytometry can be performed by defining aberrant marker expressions, the socalled leukaemia-associated phenotypes (LAPs), on malignant cells at diagnosis. [1] [2] [3] [4] [5] [6] These LAPs are not, or only in very low frequencies, present on normal blood or BM cells. This technique can be successfully applied in up to 80% of the AML patients in contrast to molecular biological techniques, which were until now applicable only in 20-30% of the cases. [7] [8] [9] So far, in AML the predictive value of MRD frequency detection using immunophenotyping has been reported by a few groups only. 6, [10] [11] [12] In adult AML patients, San Miguel et al 6, 10 demonstrated the prognostic value of MRD after induction and intensification therapy, while Venditti et al 11 have found this after consolidation therapy only. Recently, the Children's Cancer Group reported a role for MRD quantification in BM after the end of induction chemotherapy in predicting relapses in paediatric AML patients in a prospective, blinded study. 12 No study has been directed specifically to show the prognostic impact of MRD in autologous PBSC products. As stated earlier, for AML there is an urgent need for additional MRD studies both in BM samples and in autologous PBSC products. 13 In the present study, the prognostic value of such MRD frequency assessment by immunophenotyping was established in BM obtained after two different cycles of induction and one cycle of consolidation chemotherapy and, in addition, in autologous PSBC products. Since a recent MRD study in childhood acute lymphoid leukaemia showed that absolute MRD quantification was superior to relative MRD frequency in predicting the outcome, 14 we have also investigated the absolute number of MRD cells/ml. Lastly, the role of sequential assessment of MRD after the completion of treatment in predicting impending relapses was studied.
Materials and methods

Patient treatment
AML patients p60 years were treated according to the Dutch HOVON 29 (during 1998-2000) 15 and HOVON 42 (during 2001-2003) protocols, which basically have an identical design, consisting of two remission induction cycles and a consolidation cycle. The treatment scheme is shown in Figure 1a . In the HOVON 29 protocol, the first cycle included a standard dose of cytarabine (200 mg/m 2 /day, days 1-7) and idarubicin (12 mg/m 2 /day, days [6] [7] [8] and in the second cycle, an intermediate dose of cytarabine (1000 mg/m 2 /day, days 1-6) and amsacrine (120 mg/m 2 /day, days 4-6). In the HOVON 42 protocol patients were first randomized to either chemotherapy identical to HOVON 29 or to an intermediate dose of cytarabine (1000 mg/m 2 day, days 1-7) plus idarubicin (12 mg/m 2 /day, days 1-3) followed by a high-dose cytarabine (2000 mg/m 2 /day, days 1, 3, 5 and 7) plus amsacrine (120 mg/m 2 /day, days 2, 4 and 6). The sequence standard cytarabine dose in the first cycle and intermediate dose in the second cycle is referred to as 'control arm'. The sequence with intermediate dose in the first cycle followed by high dose in the second cycle is referred to as 'experimental arm'. Patients with M3-AML or AML with translocation t (15, 17) were additionally treated with ATRA 45 mg/m by leucapheresis after the second cycle of chemotherapy following G-CSF administration (lenograstim, 600 mg/m 2 /day). Patients from both protocols were then randomly assigned to a third cycle of chemotherapy consisting of mitoxantrone (10 mg/ m 2 , days 1-5) and etoposide (100 mg/m 2 , days 1-5) or a myeloablative regimen with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) followed by autologous PBSC transplantation. In case of an HLA-identical sibling or an HLAidentical unrelated donor, patients (o55 years) were eligible for an allogeneic stem cell transplantation.
Patients 460 years were treated according to the HOVON 32 protocol (Figure 1b 
Patient and treatment characteristics
After informed consent, MRD frequency was monitored in 309 follow-up samples of 72 evaluable CR patients after the first and/ or second and/or third cycle of chemotherapy in BM (n ¼ 270), as well as in autologous PBSC products (n ¼ 39). In addition, we were able to study material at relapse of 30 patients. MRD samples were obtained in 51/72 patients after the first cycle and in 52/72 and 30/72 patients after the second cycle and consolidation therapy, respectively. In 34/72 patients, we were able to measure MRD in BM samples obtained after both the first and second cycle of remission induction therapy and in 24/72 patients in BM samples obtained both after remission induction courses and after consolidation chemotherapy. If more than one BM aspiration was taken after a cycle of chemotherapy, the MRD frequency of the BM sample that was aspirated after haematological recovery was used for clinical correlations.
The clinical characteristics of the 72 AML patients used in this study were as follows: 30 men and 42 women, 52 patients younger than 60 years and 20 patients older than 60 years (median age: 50 years, range: 18-76 years), French American British (FAB) classification were as follows: M0 (6 patients), M1 (10 patients), M2 (14 patients), M3 (4 patients), M4 (15 patients), M5 (16 patients), M6 (4 patients), BAL (1 patient) and RAEB-t (2 patients). Karyotypes according to Grimwade et al: 16 12 patients had the favourable aberrations t(8,21)(q22;q22), inv16 (p13q22) or t(15,17)(q22;q21); five patients had poor prognostic features (complex karyotype, that is, a clone with at least five unrelated abnormalities, monosomies of chromosome 5 or 7, deletions of the long arm of chromosome 5 or 3q abnormalities); 53 patients were classified as intermediate (the remaining karyotypes, including the normal ones or those with structural or numerical changes not encompassed by the favourable and poor groups) while 2 patients had unknown karyotype. Complete remission was achieved after one cycle of chemotherapy in 61 (85%) patients, after two cycles in eight patients (11%) and after three cycles in three patients (4%). The median followup was 10.1 months (range: 3-53 months).
We have divided patients in subgroups representing homogeneously treated patients. The details on numbers are outlined in Table 1 . The HOVON 32 protocol for elderly patients (460 years) quite differed from the HOVON 29 and 42 protocols, in which the younger patients (p60 years) were included. These two groups are dealt with separately. The majority of patients MRD parameters predict survival in AML N Feller et al from whom MRD data were obtained were p60 years old. After the first, second and third cycle of chemotherapy, this concerned 39/51, 40/52 and 25/30 patients, respectively ( Table 1 ). The vast majority of these younger patients received the control induction therapy arm and this group was further divided into different groups based on the type of consolidation therapy either mitoxantrone/etoposide or busulphan/cyclophosphamide combined with autologous or allogeneic PBSC transplantation. A small group of patients received the experimental therapy arm in the induction chemotherapy. Based on the observation of low number, this group was not further subdivided on the basis of consolidation therapy.
MRD concerned the elderly group (460 years) in a minority of the cases: 12/51, 12/52 and 5/30 patients after the first, second and third consolidation cycle, respectively. Of these 7/ 12, 7/12 and 1/5 patients received fludarabine during the remission induction chemotherapy. Also, this group was not further subdivided considering the very low number of patients.
In the Results section, data will be presented both for the whole group of patients and subsequently for homogeneously treated subgroups based on age and transplantation as the major variables.
Establishment of LAPs
LAPs were established in newly diagnosed AML using a double step immunophenotypic labelling procedure. In the first step, a panel of 12 quadruple monoclonal antibody (Moab) combinations conjugated with either fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinyl chlorophyllin (PerCP) or allophycocyanin (APC) was used to define the immunophenotype of the blasts in whole BM or peripheral blood during diagnosis. The Moab combinations used were: (1) CD3-CD4-CD45-CD34, (2) CD15-CD13-CD45-CD34, (3) CD2-CD56-CD45-CD34, (4) CD5-CD7-CD45-CD34, (5) CD11c-CD11b-CD45-CD34, (6) CD65-CD117-CD45-CD34, (7) CD61-CD33-CD45-CD34, (8) CD71-CD19-CD45-CD34, (9) CD22-CD90-CD45-CD34, (10) CD42b-CD34-CD45-CD14, (11) HLA-DR-CD20-CD45-CD34 and (12) CD34-CD133-CD45-CD38. The conjugation of these Moabs with FITC, PE, PerCP and APC, respectively, were in the order of notation.
On the basis of the results of the immunophenotypic staining of leukaemia blasts, LAPs were defined in which, if possible, a primitive stem cell/progenitor marker (CD34, CD117 or CD133) was included. If this was not possible, an LAP was defined by combining mature markers, which were expressed on the AML blasts, with mature markers that were not expressed on the AML blasts. Use of this approach during MRD monitoring subsets of normal mature cells, which might interfere with the LAP measurement, could be excluded (eg CD14 for excluding normal monocytic cells when AML cells did not express CD14). The validity of the LAP was confirmed by a second labelling procedure and we defined that it should be present in at least 10% of the leukaemia blasts (CD45dim/SSC low cells). The immunophenotypic labelling was performed as follows: cells were incubated with the appropriate Moab combinations for 15 min at room temperature, erythrocytes were lysed with FACS lysing solution (Becton Dickinson, San Jose, CA, USA) and cells were washed twice with phosphate-buffered saline containing 0.1% bovine serum albumin (BSA). Data acquisition were performed using a FACScalibur equipped with an argon and red diode laser, and analysis was performed using Cellquest software (Becton Dickinson). The sources of Moabs conjugated with FITC were as follows: anti-CD2 and anti-CD45 from Coulter (Coultronics, Mergency, France); anti-CD5, anti-CD11c, anti-CD13, anti-CD42b, anti-CD71 and anti-HLADR from Dako (Glostrup, Denmark); anti-CD7 and anti-CD22 from CLB (Amsterdam, The Netherlands); anti-CD3, anti-CD15, anti-CD20, anti-CD34 and anti-CD61 from Becton Dickinson; anti-CD33 and anti-TdT from Caltag (San Francisco, CA, USA); anti-CD38 from Immunotech (Marseille, France); anti-CD65 from AnderGrub (Kaumberg, Austria); and anti-CD90 from Pharmingen (San Diego, CA, USA). For Moabs conjugated with PE the 
This table shows firstly, the definition of subgroups of patients both in the younger group (p60 years) and in the elderly (460 years), based on, sometimes slightly different chemotherapy, all with the size of the groups indicated within parenthesis. Further, the prognostic value of MRD for RFS is shown in the different subgroups of patients using the cutoff values as defined for the whole group: these were 1% MRD after the first induction cycle, 0.14% MRD after the second induction cycle and 0.11% MRD after the consolidation cycle. The subgroup of patients younger than 60 years was subdivided in groups receiving different cytarabine dose in the induction chemotherapy. The control therapy arm group was further subdivided into groups receiving either mitoxantrone/etoposide or busulphan/cyclophosphamide followed by an autologous transplantation or allogeneic PBSC transplantation. The subgroups that were not further subdivided due to the low numbers of patients are: elderly patients and young patients in the experimental therapy arm. NS: not significant; auto: autologous; allo: allogeneic.
n Using a cutoff value of 0.5% MRD instead of 1% resulted in significance (P ¼ 0.02). x Using a cutoff value of 0.2% MRD instead of 0.14% resulted in significance (P ¼ 0.04). y Using a cutoff level of 0.6% MRD resulted in significance (P ¼ 0.03). 
MRD detection and frequency calculation
The white blood cell (WBC) count was counted in a Neubauer counting chamber after lysis of red blood cells with ammonium chloride. In follow-up samples, about 1 Â 10 6 cells were incubated for 15 min at room temperature with Moab combinations that defined the LAP on the corresponding AML at diagnosis, lysed, washed twice and measured by flow cytometry. Data analyses were performed on the total WBC compartment characterized by CD45 expression and forward scatter (FSC), which enabled the exclusion of erythroblasts and nonlysed erythrocytes. Next, the aberrancies were analysed on cells possessing the primitive stem cell marker with a low side scatter (SSC) as established in the AML at diagnosis (for an example see Figure 2 ). For every LAP corresponding isotype controls were included. The staining of specific Moabs was not corrected for aspecific binding as tested by the isotype controls, since the latter was always less than 10% of the specific Moab binding. The maximal sensitivity of the MRD detection was 0.01% (ie 1 Â 10 À4 ) when a total of 1 Â 10 6 cells was measured. This was established in unmanufactured non-AML PBSC products with spiking experiments using AML blasts with an aberrant phenotype CD34 þ CD56 þ that covered all AML blasts (not shown). Notably, the maximal sensitivity of other types of aberrant phenotypes is dependent on the background expression on normal cells, but is mostly in between 0.01 and 0.05%. If more than one LAP was established in the AML at diagnosis, the most reliable LAP (ie high LAP expression in AML at diagnosis and low background expression on control material) was used for establishing the MRD status of the patient. The MRD frequency established was then checked using the other LAPs. Using this approach false-negativity resulting from phenotypic shifts could largely be prevented. As a last step, the MRD% was corrected for the percentage of LAP expression on AML blasts at diagnosis. Absolute numbers of MRD cells/ml were obtained by multiplying the MRD frequency with the WBC count/ml present in BM. In the Results section, the validation on whether the MRD frequency should be corrected for the background LAP expression on normal cells is presented. For this validation, 40 different LAPs were measured in three to eight allogeneic or non-AML PBSC products. Figure 2 shows two examples of patients in whom MRD frequencies after different cycles of chemotherapy were assessed: one example shows the MRD frequency in a patient who relapsed very fast (Figure 2b ) and the other, in a patient who is still in remission after 2 years (Figure 2c ). MRD detection in consecutive BM samples of a relapsing patient and of a patient still in remission. Cells from AML at diagnosis and follow-up BM samples are stained with a combination of Moabs, which identifies a LAP (see Material and methods). (a) The gating strategy starts by defining the WBC compartment characterized by CD45 expression and FSC. On these selected cells the cell population with a primitive marker expression, in this case CD34, and low SSC is subsequently gated for detection of the cells with aberrant phenotypes. (b) Example of a patient who relapsed within 6 months after achieving complete remission. The aberrant phenotype was CD117 þ and CD2 þ expression on the CD34 þ cells. The MRD% was 0.16, 0.21, and 0.19% after the first, second and third cycle of chemotherapy, respectively. Dot plot at the extreme right of the figure shows relapsed material with LAP expression similar to at diagnosis material. (c) Example of a patient who is still in complete remission after 24 months. The LAP includes CD117 and CD7 expression. After the first cycle, the MRD% was 0.12% and was below 0.01% after the other cycles.
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Outcome measures
Remission was defined as complete if less than 5% blasts were present in BM and with concomitant evidence of normal erythropoiesis, granulopoiesis and megakaryopoiesis. In addition, granulocytes and platelets in peripheral blood should be at least 1.5 Â 10 9 /l and 100 Â 10 9 /l, respectively. 17 Relapse was defined as marrow infiltration by more than 5% blasts in previously normal BM. The correlation between MRD frequency and clinical outcome was analysed only for those cases in which one or more LAPs were found in newly diagnosed AML and when complete remission was achieved based on morphological techniques plus normal blood cell counts. Relapse-free survival (RFS) was defined as the interval between the dates of complete remission and relapse, while overall survival (OS) refers to the period between the date of registration and death. Since in this study only patients who achieved complete remission were included, refractoriness and early deaths were not included in these OS data. Patients still in remission were censored in statistical analyses at the time of their last follow-up.
Statistical analysis
The w 2 and Mann-Whitney U-tests were used to estimate the statistical significance of differences between groups. Cox's regression was used for the validation of MRD measurements, the correlation between MRD frequency/absolute number and survival, the relative risk of relapse with a 95% confidence interval (CI) and for univariate and multivariate analyses. Kaplan-Meier approach was used for RFS and OS and significant differences between the different groups were calculated using log-rank test. P-values p0.05 were considered as significant.
Results
Applicability of LAPs for MRD measurements LAP frequency:
In 72 patients evaluable for MRD assessment, we were able to define one LAP in 60% of the cases and at least two independent LAPs in 40% of the cases (two LAPs in 25%, three LAPs in 10% and four or more LAPs in 5% of these cases). The LAPs of these 72 patients, which have been used for MRD detection, are shown in Table 2 . In 97% of all LAPs used (118/122), at least one primitive marker, that is, CD34, CD117 and CD133, could be included.
Phenotypic shifts: Phenotypic shifts might result in falsenegative observations. 18, 19 In order to establish the risk for this putative pitfall in our patient group, we compared 30 relapsed samples with the corresponding AML samples at diagnosis. Of the 47 independent LAPs, defined in AML at diagnosis, five LAPs (11%) had disappeared at relapse and these were distributed over three patients. In one of these patients the LAP that had disappeared was the only one present at diagnosis, while in the other two patients, one of the other LAPs had not disappeared at relapse. Thus, a phenotypic shift would have resulted in a falsenegative MRD measurement only in one out of the 30 patients studied (3%), and this was specifically due to the fact that only one LAP was available for MRD monitoring.
LAP distribution in malignant blasts: In the majority of the cases an LAP is not expressed on 100% of the leukaemia blast population (minimum LAP expression on blasts: 10% and median LAP expression on blasts: 43%). To approach the frequency of the total leukaemia blast population in an MRD situation, we have chosen to correct the LAP expression on AML blasts at diagnosis. A prerequisite for allowing such corrections is the stability of relative frequency of a LAP in the course of disease. Although this cannot be studied directly since the different LAPs do not comprise all blasts, this was studied indirectly in MRD material in 22 cases by comparing the relative frequencies of the subpopulations with the different LAPs Figure 3 shows the four clearest examples of the finding that the relative frequencies of the LAP subpopulations were in general unaltered in MRD samples compared to the corresponding samples at diagnosis.
Background staining of LAPs in normal cells: Correction of the MRD frequency for LAP expression on AML at diagnosis may result in a too high MRD frequency due to the presence of a low percentage of normal cells expressing the particular LAP.
We have validated the impact of such background staining on MRD assessment. Based on our extensive experience with PBSC products, the validation has been performed herein. The background of the LAPs was measured in PBSC products from non-AML patients and allogeneic donors. Next, the frequency of a specific LAP, which was measured in an AML PBSC product, was corrected for this background staining. After that, both the noncorrected and background-corrected LAP frequencies were corrected for the percentage of LAP expression on AML at diagnosis, as discussed in the previous paragraph. We found that both the background-corrected and the noncorrected MRD frequency correlated very significantly with RFS (Pp0.0001 for both approaches). Based on these results, we decided not to include background correction in the follow-up samples.
MRD frequency in BM and clinical outcome
We have chosen to define cutoff levels for MRD in relation to survival firstly in the whole group of patients, and subsequently, to assess the applicability of these cutoff levels for the subgroups as defined in Table 1 .
MRD frequency after the first cycle of chemotherapy:
After the first cycle of remission induction chemotherapy, we received BM samples from 51 patients in complete remission for MRD detection. MRD frequency inversely correlated with both RFS (P ¼ 0.002) and OS (P ¼ 0.02). A cutoff level of 1% MRD identified two groups of patients with the most significant difference in RFS (Figure 4a ) and OS (P ¼ 0.010, data not shown). Patients with 41% MRD showed a 6.1-fold (95% CI ¼ 2.4-15.7, P ¼ 0.0002) higher relative risk of relapse (Table 3) . Other cutoff levels, that is, 0.3 and 0.8%, also resulted in two groups with significantly different RFS (P ¼ 0.04 and 0.01, respectively). Difference in RFS remained when the whole group was divided based on age, even in the small subgroup of 12 elderly patients (Table 1) . Within the younger patients the subgroup, which received the experimental induction therapy arm (n ¼ 7), was too small to analyse separately, but the group with the standard dose (n ¼ 32) still showed a significant difference in RFS (Table 1) . This group of patients was further subdivided based on the type of consolidation chemotherapy. Remarkably, both in the patient groups treated according to the mitoxantrone/etoposide arm and the autologous PBSC transplantation arm, the MRD cutoff level of 1% still identified two groups of patients with a significantly or almost significantly different RFS, despite the low number of patients (n ¼ 15 and 11, respectively). As expected, based on the size of the groups no subgroups with significant differences in RFS were found in the small group that received an allogeneic stem cell transplantation (n ¼ 6).
MRD frequency after the second cycle of chemotherapy: After the second cycle of remission-induction chemotherapy, a strong inverse correlation was found between MRD frequency and both RFS (P ¼ 0.0003) and OS (P ¼ 0.004) for the 52 evaluable patients. Now, the median cutoff value of 0.14% MRD identified two distinct groups of patients with the highest significance for the difference of RFS (Figure 4b ) and OS (P ¼ 0.001, data not shown). The relative risk was now 3.4-fold (95% CI ¼ 1.5-7.8, P ¼ 0.003) higher in the group with 40.14% MRD (Table 3 ). An important observation is that this particular cutoff level is not unique in identifying two groups of patients with different outcomes: for example, cutoff levels of 0.06, 0.1, 0.2, 0.6 and 1% also resulted in two groups with significantly different RFS (in all cases: Pp0.02). The subgroup analysis offered results quite similar to the first induction cycle (for details see Table 1 ). It is noteworthy that in patient groups including the allogeneic-transplanted patients, who showed no significance at the predefined cutoff level of 0.14%, slightly different cutoffs sufficed (see legend of Table 1 ).
MRD frequency after the third cycle of chemotherapy: Also, after consolidation therapy the MRD frequency correlated 
with the clinical outcome, as measured in 30 evaluable patients. In the total group again MRD frequency inversely correlated both with RFS (P ¼ 0.003) and OS (P ¼ 0.002). A cutoff value of the median MRD% of 0.11 resulted in the most significant difference in RFS (Figure 4c ) and OS (P ¼ 0.001, data not shown). The relative risk of relapse was 7.2-fold (95% CI, 1.9-27.6, P ¼ 0.004) higher at high MRD% (Table 3) . Also, other cutoff levels, like those after the second cycle, that is, 0.06, 0.1, 0.2, 0.6 and 1%, all resulted in groups with significantly different RFS (in all cases: Pp0.02). A subgroup analyses of the elderly patient group (based on fludarabine treatment) resulted in subgroups too small to analyse (n ¼ 5). Within the younger patient group the subdivision of the patient group receiving the standard dose of cytarabine finally resulted in small groups (mitoxantrone/etopside arm: n ¼ 12 and autologous PBSC arm: n ¼ 8), which nevertheless revealed two patient groups with significant differences in RFS. The experimental induction therapy arm and the allogeneic PBSC arm were too small for subdivision.
In conclusion, after each cycle of chemotherapy the MRD% is predictive for RFS and OS. The MRD% was obtained after correction for the percentage LAP expression on AML blasts, but MRD% was also predictive for the outcome without correction. As shown before, the relative risk of relapse for the whole group of patients with correction was 1.30 (1.10-1.52), P ¼ 0.002 after the first cycle, 2.04 (1.38-3.02) after the second cycle, P ¼ 0.0003 and 1.60 (1.17-2.19), P ¼ 0.0032 after the third cycle. Without correction the relative risk of relapse was 2.54 (1.13-5.72), P ¼ 0.024 after the first cycle, 1.60 (1.17-2.19), P ¼ 0.0032 after the second cycle and 1.78 (0.88-3.60), Figure 4 Prognostic value of MRD frequency in BM after the first, second and third cycle of chemotherapy and in PBSC products. MRD frequency was measured after the first cycle of chemotherapy in 51 BM samples (a), second cycle of chemotherapy in 52 BM samples (b) and third cycle of chemotherapy in 30 BM samples (c) and in 39 PBSC products (d). At different cutoff levels MRD frequencies below and above this level were correlated with RFS. (a) RFS correlated with MRD in BM after the cycle using a cutoff level of 1% MRD. The median RFS was 25.4 months at p1% MRD (n ¼ 6) and 3 months at 41% MRD (n ¼ 42). The cutoff level of 1% was chosen to have the largest significances in differences between the groups. The median cutoff level (0.19% MRD) yielded no significant differences but somewhat higher cutoff levels of MRD% resulted in a significantly different RFS between the two patient groups (P ¼ 0.04 and 0.01 at cutoff levels of 0.3 and 0.8% MRD, respectively). (b) RFS correlated with MRD in BM after the second cycle using a cutoff level of the median MRD% of 0.14%. The median RFS was 28.5 months at p0.14% MRD (n ¼ 26) and 6.5 months at 40.14% (n ¼ 26). Differences in RFS were also significant in the range of cutoff levels of 0.06-1% (Pp0.02). (c) RFS correlated with MRD in BM after the third cycle using a cutoff level of 0.11% MRD. The median RFS was 47 months in the group with MRD p0.11% (n ¼ 15) and 11 months in the group with 40.11% MRD (n ¼ 15). (d) RFS correlated with MRD in PBSC products using a cutoff level of 0.13% MRD. The median RFS was 27.8 months at p0.13% MRD (n ¼ 19) and 5.7 months at 40.13% (n ¼ 20). Differences in RFS were also significant in the range of cutoff levels of 0.06-1% (Pp0.02). Table 3 Relative risk of a relapse defined by MRD frequency in BM and PBSC products MRD parameters predict survival in AML N Feller et al P ¼ 0.11 after the third cycle. Other prognostic parameters in the total patient group were cytogenetics (P ¼ 0.02) and the number of cycles of chemotherapy to achieve complete remission (P ¼ 0.02). No correlation between the MRD% and subgroups of patients based on differences in cytogenetics and number of cycles to achieve complete remission could be found. In the MRD survival analyses shown for the whole patient group (n ¼ 72), transplantation (autologous and allogeneic) has been included. In this group of patients there was no significant difference in RFS between the patients who received the standard dose of chemotherapy or the high dose followed by autologous or allogeneic PBSC transplantation, and for that reason the type of consolidation chemotherapy did not interfere with the prognostic value of MRD. However, in the subgroup of patients in which MRD was measured after the second induction cycle (n ¼ 52), the treatment of patients with allogeneic PBSC transplantation resulted in a significantly longer RFS (P ¼ 0.05). After censoring the patients who received an allogeneic stem cell transplantation (n ¼ 7), in the patient group with high MRD, the relative risk of relapse was increased from 3.4-fold (95% CI ¼ 1.5-7.8, P ¼ 0.003) to 4.2 (95% CI, 1.8-10.0, P ¼ 0.001).
Multivariate analyses revealed that MRD frequencies, as measured in the whole group of patients after the first, second and third cycle, were independent of age, cytogenetics, WBC count in diagnosis material, FAB classification, number of cycles to achieve complete remission and treatment differences in the prediction of survival (data not shown). Furthermore, the MRD% after all cycles appeared to be the most powerful prognostic factor.
MRD frequency in autologous PBSC products
After the second cycle of chemotherapy in patients p60 years in complete remission, autologous PBSC were collected. These patients were subsequently randomized for either high-dose chemotherapy followed by PBSC transplantation or a third cycle of standard dose of chemotherapy. The MRD frequency present in autologous PBSC products correlated significantly with the MRD frequency in BM after the second cycle (Po0.0001), as measured in 26 paired samples. This indicates that MRD frequency present in PBSC products reflects the MRD frequency present in BM. The MRD frequency, as established in 39 PBSC products, inversely correlated both with RFS (P ¼ 0.0001) and with OS (Po0.0001). At a cutoff level of 0.13%, which is the median MRD%, RFS was significantly different between the two groups of patients, as shown in Figure 4d . Also, the relative risk of relapse was significantly different with a 5.7-fold (95% CI, 2.4-13.7, P ¼ 0.0001) difference between both groups (Table 3) . Similar to the BM data after the second and third cycle of chemotherapy, other cutoff levels, that is, 0.06, 0.2 and 0.6%, resulted in significantly different RFS (for all cutoff levels Pp0.0005). Also, the predictive value of MRD% was independent of both the cytarabine dose in the induction therapy and type of consolidation chemotherapy (standard dose or high-dose chemotherapy followed by PBSC transplantation).
Number of MRD cells/ml as prognostic factor
We hypothesized that the variation of the tumour load at the start of chemotherapy, reflected both by the percentage of malignant cells and the absolute number of malignant cells cells/ml, might affect the efficacy of the subsequent treatment. On diagnosis, of the group of 51 patients, the absolute number of malignant cells/ml varied 220-fold (range: 1.3 Â 10 6 cells/ml-260 Â 10 6 cells/ml). After the first cycle of chemotherapy and before the second cycle, both the MRD frequencies (range: p0.01-5%, factor: X500) and the cell concentrations (range: p1000 cells/mlÀ1.2 Â 10 6 cells/ml, factor: X1200) showed large variations. We found an inverse significant correlation between the absolute number of MRD cells/ml and RFS (P ¼ 0.03 and 0.006, respectively) after the first and second cycle of chemotherapy. Moreover, after the second cycle we could define various cutoff levels (2.5 Â 10 4 , 5 Â 10 4 , 7.5 Â 10 4 and 10 Â 10 4 MRD cells/ml) that identified the two different groups of patients with significantly different RFS. The best statistically significant correlation was found using a cutoff value of 5 Â 10 4 MRD cells/ml (P ¼ 0.0003). Of the patients, 56% had more than 5 Â 10 4 MRD cells/ml in BM and the relative risk of relapse of these patients was estimated to be 4.8 (95% CI ¼ 2.1-11.2, P ¼ 0.0003). The absolute number of MRD cells/ml could not be used reliably for correlations after the third cycle of chemotherapy, since in most cases the MRD frequencies after the second cycle were already at or below the detection level.
MRD detection after the end of treatment
After the chemotherapy ends, sequential assessment of MRD frequencies was used to explore it as a prognostic tool for predicting impending relapses. MRD frequency was measured in 69 BM samples of 24 patients at different time points after the end of protocol treatment. Figure 5 illustrates the fates of these patients in an ongoing evaluation for each patient after the end of treatment. Figure 5a shows the results for patients who started with o0.11% MRD (the cutoff value found earlier after third cycle, Table 1 ). Nine out of 15 patients started below the cutoff level of 0.11% and remained at this level during evaluation (range 8-38 months). This group included two patients who received allogeneic stem cell transplantation. Three out of six remaining patients relapsed after 4, 5 and 7 months before follow-up samples could be analysed. The other three patients manifested the following: in one patient the MRD frequency had increased up to 4% after 5 months, while after 7 months a clinical relapse was obvious. In the second patient, the MRD status was below the detection level during 19 months follow-up, as measured in four consecutive BM samples. This patient relapsed, however, 8 months after the last MRD measurement. In the third patient, a gradual increase of MRD frequency was obvious, starting from 18 till 29 months after the end of therapy. After 44 months, a clinical relapse was established in a bone biopsy of this patient. Figure 5b shows the results for patients starting with 40.11% MRD after the end of treatment. Nine patients started with 40.11% MRD and seven of these patients relapsed within 8 months, including a patient who received an allogeneic transplant (Figure 5b) . Remarkably, the only two patients who did not relapse, but in fact showed a decrease of the MRD frequency, were those who were treated with high-dose chemotherapy followed by allogeneic stem cell transplantation.
Discussion
In the present study, we found that MRD frequency, as measured by immunophenotyping in BM is a highly reliable predictor of RFS and OS after chemotherapy. Using an MRD cutoff value of 1% after the first induction cycle, the median cutoff values of 0.14% MRD after the second cycle of induction chemotherapy and of 0.11% after the consolidation chemotherapy, we could define two groups of patients with significantly different relative risks of relapse. If the MRD frequency was above the cutoff values, the relative risk of relapse was a factor 3.4-and 7.2-fold higher, respectively, compared to the group of patients with MRD below these cutoff levels. It is noteworthy that various other cutoff levels for defining groups with significantly different survival could be established in a wide range of MRD frequencies (range: 0.06-1%), illustrating the strength of the correlations.
A critical factor for monitoring MRD is the constitution of an aberrant LAP in newly diagnosed AML samples. An important prerequisite for a LAP with regard to its specificity for leukaemia cells is that LAP expression on normal blood and BM cells should be absent or as low as possible. A relatively low 'background' staining can be achieved by including a primitive marker, which in normal BM and blood is already expressed in low frequencies. A second lead to include a primitive marker is the presumed leukaemogenic ability in this marker-defined cell population, which is likely to be responsible for outgrowth of the disease. Another prerequisite is the stability of an LAP during the course of the disease. We have found no indications either for an increased sensitivity of a specific LAP-defined subpopulation in response to the chemotherapeutic treatment or for outgrowth at the relapse of a specific subpopulation. It has to be noted that we have not studied the more mature subpopulations, which may be associated with other outgrowth and therapy sensitivity characteristics. Nevertheless, an LAP may disappear due to phenotypic shifts, which in fact occurs in 11% of the LAPs in our study. We and others 18, 19 have shown that this is not necessarily a serious pitfall, provided that more than one independent LAP is used. Using this approach, false-negative results due to phenotypic shifts still may occur but at a much less frequency: in this limited study only in 3% of the patients.
We have compared our MRD data with those of three other groups, which reported prognostic impact of MRD frequency using immunophenotypic detection methods. 6, [10] [11] [12] Considering the cutoff levels for distinguishing two patient groups with different clinical outcome, Venditti and co-workers were not able to establish such a cutoff level after one cycle of induction chemotherapy. 11 On the other hand, San Miguel et al 6 and Sievers et al 12 established a cutoff level of 0.5% after one or two cycles of induction chemotherapy, which is quite similar to our cutoff level of 1%, established after one cycle of induction chemotherapy. Furthermore, after consolidation chemotherapy two patient groups with different RFS could be defined at a cutoff level of 0.035% in the study of Venditti et al and 0.2% in the study of San Miguel et al. We found significant correlations using a cutoff level of the median MRD% of 0.14 after the second induction and a cutoff level of the median MRD% of 0.11 after consolidation therapy. An important fact is that the cutoff levels are not unique in identifying two groups with different outcomes: apart from the median cutoff levels, a broad range of different cutoff levels, varying from 0.06 to 1%, also resulted in significant differences in RFS. In a later study of San Miguel et al, 10 four different risk categories were identified based on MRD frequencies from the first BM sample in morphologic remission after one or two cycles of chemotherapy. Patient groups with p0.01% MRD, 0.01-0.1% MRD, 0.1-1% MRD and 41% MRD showed increasing relapse rates at 3 years of 0, 14, 50 and 84%, respectively. However, in that study patients received one or two cycles of induction chemotherapy, whereas we discriminated between the MRD frequency after the first and second cycle of induction chemotherapy, showing a more reliabe prediction of the clinical outcome after the second cycle.
In the present MRD study, the whole patient group can be subdivided into smaller groups treated with different regimens. Whether this is necessary is a matter of debate. It could be hypothesized that differences in the dosage of an anticancer drug, such as for cytarabine in the different HOVON protocols will not necessarily affect the predictive power of MRD: a fixed dose of an anticancer agent due to differences in pharmacology and pharmacokinetics already results in actual differences among patients in drug concentrations at target. 20 The use of a higher dose, resulting in a large continuum of actual concentrations, result in a direct correlation with MRD, which is now independent of the dose used. Similarly, it is not even likely that different types of anticancer drugs would result in different types of MRD cells, for example, with such differences in clonogenic characteristics that would abrogate the relationship between MRD frequency and outgrowth characteristics. In this philosophy, MRD frequency is a prognostic factor, which is independent of dose, delivery scheme and type of anticancer drug. In agreement with this, in the whole group of patients no difference in survival was found in patient groups, who were treated differently. As expected, multivariate analyses showed that the predictive value of MRD was independent of differences between treatment schedules, except for the allogeneic transplant group (see below). These theoretical considerations were investigated by subdividing patients in groups based either on age or randomization of the young patient group, who received the control therapy arm. Remarkably, despite the fact that all subgroups were small or even very small in number, we found that in most subgroups cutoff levels could be defined that identified two groups of patients with a significant difference in RFS. In almost all cases, these cutoff levels were similar to those found in the whole group. The number of patients present in these subgroups are, however, too small to draw conclusions on whether the cutoff values for these subgroup of patients were the most optimal ones.
As referred to earlier, it is the group of patients treated with high-dose chemotherapy followed by allogeneic transplantation that forms an exception. Leukaemia cells are not only killed by chemotherapy but also by a graft-versus leukaemia effect, which is clearly not confined like chemotherapy to a particular period, but may represent long-lasting effects. Therefore, theoretically this interferes with the predictive value of MRD as measured on clearly defined time points. This is best illustrated in Figure 5 , which strongly suggests that in patients with poor prognosis based on MRD frequency, only allogeneic transplantation is able to cause a strong decrease of MRD frequency. In that respect, one might expect that censoring the allogeneically transplanted patients might improve the prognostic value of MRD. Indeed, after censoring the allogeneic-transplanted patients of the patient group in which MRD was measured, after the second course of induction chemotherapy, the predictive value of MRD improved.
So far, immunophenotypic detection methods have been used almost exclusively for assessing the MRD frequencies in BM. The incorporation of autologous stem cell transplantation in many treatment protocols and the, as yet, unsettled clinical impact of tumour contamination in transplants warrants MRD assessment in PBSC products. We have shown that MRD frequency in PBSC products, which varied from p0.01 to 2.0%, could not only be used to assess the quality of the product but also to predict both RFS and OS. Such a correlation between MRD frequency in PBSC products and RFS has also been described in another study, which was focused on the relation between MRD frequency and impaired megakaryocytic clonogenic growth. 21 In a previous study, 22 we used MRD frequency in PBSC products to explain that a high percentage of CD34-positive cells in PBSC products is an adverse prognostic factor. Notably, in that study RFS turned out to be independent of the actual use of the PBSC product. We now show that the MRD frequency as measured in PBSC products, which was obtained after the second cycle of chemotherapy following G-CSF mobilization, seemed to be as good in predicting the outcome as the corresponding BM after the second cycle. Again, the predictive value was independent of the actual use of the PBSC product. Although the latter suggests that tumour contamination in PBSC products does not significantly affect relapse rate, definite proof for this is still missing. These clinical findings together with the correlation found between MRD frequencies in PBSC products and BM after the second cycle, at least strongly indicate that MRD contamination in PBSC products is a good reflection of the leukaemia burden in the corresponding BM.
It would be of potential importance to be able to predict forthcoming relapses based not only on MRD frequency at a given time point but also on increases of MRD frequency in time. Such an approach has been shown to be successful for AML patients with evaluable chromosomal aberrancies. 9 Our analysis of MRD frequencies, assessed sequentially in BM samples taken from patients in complete remission after treatment, showed the following results. Firstly, in the patients with MRD40.1%, time intervals between the last time point measured and relapse varied between 3 to 9 months. Secondly, after the last MRD measurement, in which the MRD frequency was below the cutoff level of 0.11%, three patients relapsed 4, 5 and 7 months later. In order to be able to predict relapses, it thus seems a prerequisite to sample BM at least every 3 months similar to PCR-based MRD detection. 9 Thirdly, among the patients with p0.11% MRD, patients can be identified with more gradually increasing levels of MRD. Such increases of MRD frequency, as illustrated in our study, ask for future clinical intervention with new therapies. In conclusion, there is a remarkably large heterogeneity in the kinetics of increase of MRD frequency. It thus seems that additional to the frequency and number of MRD, other factors such as differences in proliferation rate of AML cells, 23 quality of stroma and immune surveillance are also likely to contribute to patterns of outgrowth kinetics. Our results are compatible with a recent study of Venditti et al, 24 who showed that sequential MRD monitoring after PBSC transplantation may allow the prediction of an impending relapse. In addition, similar to our study he showed that even in small groups MRD, measured in BM before transplantation, is very powerful in predicting the clinical outcome.
In summary, the present study showed that MRD monitoring using LAPs offers a reliable prognostic tool in predicting the clinical outcome in AML. This asks for risk stratification and development of patient-tailored, postremission chemotherapy. Experimental therapies, such as immunotherapy or Moab treatment, might be applied after standard chemotherapy treatment in those cases where MRD frequencies exceed a fixed level and/or with increasing MRD frequencies monitored by sequential follow-up sampling with maximal intervals of 3 months. It is important that risk stratification and intervention be performed in large randomized studies.
